DrUcheBooks, Uchenna Okagbue Njiaju MD FACP

Nigerian-American 🇳🇬 🇺🇸 millenial, ⭐️Bio writing ✍️ ⭐️ Hem/Onc Doc #Onctwitter🩺 @UniversityofZim @uchicagomed ⭐️Tweets my opinion, Retweets NOT endorsement

[DrUcheBooks, Uchenna Okagbue Njiaju MD FACP @druchebooks]

@ErikaHamilton9 I guess we can say the cons outweigh the pros. I wonder if a pos ctDNA assay might encourage uptake of adj CDK 4/6i for those initially refusing?

[DrUcheBooks, Uchenna Okagbue Njiaju MD FACP @druchebooks]

Hmm….

Patients still asking for MRD assays….what to do?

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Love this. Short and to the point.

Agree biggest takeaways for me were:

1) anthra for RS>31 (traditionally we used N+) 🔆

2) PATINA 15 month ⬆️ PFS w/ Palbo addition after THP induction

3) DO NOT 🚫USE MRD outside of a trial

@SABCSSanAntonio
#SABCS24
@OncoAlert

[DrUcheBooks, Uchenna Okagbue Njiaju MD FACP @druchebooks]

MBC HR POs treatment algorithm
@SABCSSanAntonio #SABCS24

[DrUcheBooks, Uchenna Okagbue Njiaju MD FACP @druchebooks]

I totally agree. It’s also time to move on from purely adj IO (without neoadj) IO. We should channel efforts towards identification of predictive biomarkers @SABCSSanAntonio #SABCS24

[Dr Amol Akhade @SuyogCancer]

How many trials we Need to understand that atezolizumab is probably weakest IO and we should stop testing it in IO trial .
GeparDouze - perioperative IO in Early TNBC is negative.
Time to Move On from Atezolizumab. @stolaney1 @hoperugo @5_utr @ErikaHamilton9 @OncoAlert @Larvol @SABCSSanAntonio #SABCS24

[DrUcheBooks, Uchenna Okagbue Njiaju MD FACP @druchebooks]

Treatment algorithm for HER2 pos MBC in 2024 from Dr Danso @SABCSSanAntonio #SABCS24

[DrUcheBooks, Uchenna Okagbue Njiaju MD FACP @druchebooks]

Treatment algorithm for HR pos HER2 neg MBC in 2024, including HER2 low and ultra low, by Dr Danso
@SABCSSanAntonio #SABCS24

[DrUcheBooks, Uchenna Okagbue Njiaju MD FACP @druchebooks]

Excellent summary by Dr Danso 👏🏾👏🏾👏🏾
@SABCSSanAntonio #SABCS24

[SABCS @SABCSSanAntonio]

Michael Danso closes the #SABCS24 Year in Review session by showcasing the most important developments over the past year in the research and treatment of advanced breast cancer.
@UTHealthSAMDA @AACR

[DrUcheBooks, Uchenna Okagbue Njiaju MD FACP @druchebooks]

This was an excellent summary by Dr Tsang @SABCSSanAntonio #SABCS24 👏🏾👏🏾👏🏾

[SABCS @SABCSSanAntonio]

Janice Tsang discusses the latest advances in early breast cancer research and treatment during the Year in Review session at #SABCS24.
@UTHealthSAMDA @AACR

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 Multimodal Integration of Real World Clinical and Genomic Data for the Prediction of CDK4/6 Inhibitors Outcomes in Patients with HR+/HER2- Metastatic Breast Cancer by @PedramRazaviMD 👏🏻

#SABCS24 #day4 @OncoAlert #OncoAlertAF

[Sara Tolaney @stolaney1]

GeaprDouze (NSABP B-59) preop chemo+/- atezo in early TNBC

4 yr EFS 81.9% vs 85.2%, HR 0.80, p=0.08
OS HR 0.86
Nodal Status: N+: HR: 0.62, n-: HR 1.0
pCR: 57% vs 63.3%

Atezo did not add significant benefit in EFS

@SABCSSanAntonio #SABCS24 @OncoAlert #bcsm

[Mridula George @MridulaGeorgeMD]

Takeaways from ZEST
📌short lead time between det of ctDNA and recurrence ~5mos
📌Pts who had ➖ ctDNA conv to➕within 3mos with MBC on imaging.
📌 pts with ctDNA have💯recurrence
📌 no data yet that intervening on ➕ctDNA improves outcome.
@OncoAlert #SABCS24

[Elisa Agostinetto @ElisaAgostinett]

At #SABCS24 GS3

Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cance - a post-hoc analysis of TAILOR-X

Significant benefit in DRFI and DRFS with anthracyclines in this population

@OncoAlert

[DrUcheBooks, Uchenna Okagbue Njiaju MD FACP @druchebooks]

I’ve typically recommended AC-T for the super-high Oncotype RS cases. It’s great to see data supporting this practice. Well done to the @UChicagoMed team
@SABCSSanAntonio #SABCS24

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

In TAILORx (LN- HR+) pts w/ RS≥31 addition of anthracycline results in benefit in 5-yr DRFI (5% HR 0.32) vs TC

📏benefit most clear in tumor >2 cm

↗️Increasing RS≥31 corresponded to increasing benefit of addition of anthracycline

#SABCS24 @SABCSSanAntonio @OncoAlert

[Sara Tolaney @stolaney1]

INSEMA: SLNB vs no SLNB
iDFS events 91.7% vs 91.9% , n=4858
5 yr OS :96.9 vs 98.2%

Omitting SLNB in pts with early breast cancer and cN0 and s/f breast-conserving tx did not result in inferior outcome

Now in @NEJM

@SABCSSanAntonio #SABCS24 @OncoAlert

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

It's a difficult topic to discuss- weight. Hugely personal, not easy to change, but impt.

4% ⬆️ recurrence in pts w/ node + #bcsm obese vs. lean

2% ⬆️ recurrence in pts with N0 dz

📌Magnitude of effect larger among premeno.

📌ER + AND ER neg

@SABCSSanAntonio
#SABCS24

[DrUcheBooks, Uchenna Okagbue Njiaju MD FACP @druchebooks]

I’m a bit uncertain here with OS immature at 78 month f/u
Are we going to have a replay of the PALOMA story?
@SABCSSanAntonio #sabcs24

[Paolo Tarantino @PTarantinoMD]

‼️When you thought you had the #SABCS24 program figured out, here’s the PRACTICE-CHANGING #PATINA trial being added!

For the impatient ones, press release here: https://t.co/C3HIxbSnRb

If you’re able, though, make sure to attend the data presentation today by @Otto_DFCI! #bcsm

[DrUcheBooks, Uchenna Okagbue Njiaju MD FACP @druchebooks]

“ADCs are not available everywhere”…..a reminder at #sabcs24 Case Discussions. #healthdisparities #GlobalHealth @SABCSSanAntonio

[DrUcheBooks, Uchenna Okagbue Njiaju MD FACP @druchebooks]

This was great to see! I agree that we should probably extrapolate to PALB2 mutated. How to sequence olaparib with adj pembro +/- xeloda?
@SABCSSanAntonio #sabcs24

[Priscila Barreto Coelho, MD @PriscilaBCMD]

At 10 years of follow-up, data from the Olympia trial continues to strongly support the use of adjuvant olaparib for BRCA-positive, HER2-negative breast cancer patients. Nicely presented by @judygarber5

#SABCS2024 #BreastCancer #BRCA
@SylvesterCancer

[DrUcheBooks, Uchenna Okagbue Njiaju MD FACP @druchebooks]

This was an interesting paper. Equally interesting was the question of, “How much chemo is too little?” pCR is a surrogate for overall outcomes but without ctDNA or other microscopic level evaluation, can we ever be confident re: longterm outcomes? @SABCSSanAntonio #sabcs24

[Pablo Mando @PabloMando]

TRAIN-3 results: Are we ready to stop neoadjuvant treatment based in MRI in HR-/HER2+? #SABCS2024

[DrUcheBooks, Uchenna Okagbue Njiaju MD FACP @druchebooks]

This is promising! I’m keen on an abema-based combination/doublet regimen that’s 💯 orally administered

@SABCSSanAntonio #sabcs24

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

“It is impressive that the combination [of imlunestrant and abemaciclib] seems to tower above the rest” —@DrHBurstein, sharing his self-proclaimed dreaded cross trial comparison (students, biostatisticians: *avert your eyes*) #SABCS24 @OncoAlert